Factor II and fibrinogen for treatment of haemostatic disorders
US9433664B2 · kind B2 · utility
0Cited by
3References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 19, 2011 |
| Grant date | Sep 6, 2016 |
| Priority date | — |
| Expiry date | Jan 5, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to normalizing impaired haemostasis comprising administering a clotting factor treatment selected from the group consisting of (1) FII; (2) PCC; and (3) a three factor combination of FH, FX and FVIIa. The clotting factor treatment can be administered in combination with fibrinogen. The clotting factor(s) can be recombinant human clotting factor(s).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.